科研动态期刊摘要

[评论] 坎格瑞洛用于心肌梗死相关心源性休克

The Lancet Online First · 2026-11-14

摘要

急性心肌梗死相关心源性休克(AMI-CS)促发了一种独特的血栓形成与出血风险并存且相互竞争的复杂局面。减轻这些关键事件的策略是降低AMI-CS患者仍然承受的高死亡率的一个可行靶点。1,2 由于直接经皮冠状动脉介入治疗(PCI)是AMI-CS的基石性预后治疗手段,3 在此背景下确定最佳双联抗血小板治疗(DAPT)是一项临床优先事项,但很大程度上仍属未知领域。

English
[Comment] Cangrelor for myocardial infarction-related cardiogenic shock

Acute myocardial infarction-related cardiogenic shock (AMI-CS) fosters a unique combination of opposing, competing thrombotic and haemorrhagic risk. Strategies to mitigate these crucial events represent an actionable target to reduce the high mortality that still burdens AMI-CS patients.1,2 With primary percutaneous coronary intervention (PCI) being the cornerstone prognostic treatment of AMI-CS,3 the identification of an optimal dual anti-platelet therapy (DAPT) in this setting is a clinical priority, but remains largely uncharted.

内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界